trending Market Intelligence /marketintelligence/en/news-insights/trending/VbK1BJVNntKjtAIpTO00-g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Forward Pharma shareholders approve capital reduction

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Forward Pharma shareholders approve capital reduction

Forward Pharma A/S shareholders approved a previously announced capital reduction under which the company will buy about €917.7 million worth of shares at €19.45 apiece.

The vote was held at the company's Aug. 2 extraordinary general meeting.

The company said that based on a ruling by Danish tax authorities, it will not withhold any part of the proceeds from the planned distribution to its shareholders and holders of its American depositary shares.

The program is subject to a four-week waiting period from the publication date of the extraordinary general meeting's resolution by the Danish Business Authority.